

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, B57; Cw6, Cw7; DR7, DR15; DQ6, DQ9

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	34	34	34	34	21	20	20	21			
Positive	0	0	2	3	1	2	15	3			
Negative	34	34	32	31	20	18	5	18			
NT/Equivocal	3	3	3	3	7	8	8	7			
% Positive	0.0%	0.0%	5.9%	8.8%	4.8%	10.0%	75.0%	14.3%			
% Negative	100.0%	100.0%	94.1%	91.2%	95.2%	90.0%	25.0%	85.7%			
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative			
HLA Antibody Specificity (Defined By CDC)	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1			
			Without DTT				Without DTT				
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
112	YES	NO	Negative	Negative	Negative	Negative					
119	YES	NO	Negative	Negative	Negative	Negative					
120	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
128	YES	NO	Negative	Negative	Negative	Negative					
133	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
139	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low viability of B cells
143	YES	NO	Negative	Negative	Negative	Negative					
147	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
154	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
157	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	
159	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
181	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
189	YES	NO	Negative	Negative	Negative	Negative					
190	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Not tested due to poor viability for B cells
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
195	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cell mortality too high for valid interpretation
197	YES	YES	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
209	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
216	YES	NO	Negative	Negative	Negative	Negative					
223	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cells not tested due to low viability
229	YES	NO	Negative	Negative	Negative	Negative					
232	YES	NO	Negative	Negative	Positive	Negative					
235	YES	NO	Negative	Negative	Negative	Negative					
238	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
245	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
252	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	
260	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	
262	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Results could not be interpreted due to the poor cell viability
292	YES	YES	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Negative	
293	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
294	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Equivocal	Negative	Poor cell viability lead to difficult interpretation on B cells. Routinely another cell sample would be requested
321	YES	YES	Negative	Negative	Negative	Positive	Negative	NT	Positive	Positive	B cell serum 2 uninterpretable due to low viability on negative control
351	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Delay in receiving samples, viability <10%

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	1	2	2	2					70		
119	1	1	1	1					95		
120	1	1	1	1	1	1	8	1	99		
128	1	1	1	1					95		
133	0	0	0	0	0	0	8	0		90	60
139	1	1	1	1	NT	NT	NT	NT	80	80	
143	1	1	1	1					90		
147	1	1	1	1	1	4	6	1		100	100
154	1	1	1	1	1	1	1	1	99	99	99
157	1	1	1	1	1	1	6	4	80	80	50
159	1	1	1	1	1	1	1	1		90	80
169	1	1	1	1	1	1	8	1		99	96
181	1	1	1	1	1	1	4	1		100	100
189	1	1	1	1					88		
190	1%	1%	1%	1%	NT	NT	NT	NT		99	NT
193	1	1	1	1	1	1	4	1	99	99	90
194	-	-	-	-	-	-	8	-	100		
195	1	1	1	1	NT	NT	NT	NT	80		20
197	-	-	weak	weak	-	-	weak	weak	90	85	85
209	1	1	1	1	1	1	8	1	95		
216	1	1	1	1					85		
223	-	-	-	-	NT	NT	NT	NT		100	65
229	-	-	-	-					90		
232	0	0	2	0					80		
235	1	1	2	1					85		
238	1	1	1	1	1	1	8	1	95	90	60
245	1	1	1	1	1	1	8	1	100	100	100
252	1	1	1	1	1	1	1	1	75		55
259	NT	NT	NT	NT	NT	NT	NT	NT	85	85	85
260	NT	NT	NT	NT	NT	NT	NT	NT		70	30
262	-	-	-	-	-	-	-	-	100	100	100
292	-	-	-	4	6	8	-	-		96	20
293	-	-	-	-	-	-	8	-		80	80
294	0	0	0	0	0	0	8	2		95	95
297	1	1	1	1	1	1	2	1	70	70	70
321	1	1	1	2	1	NT	8	2		95	98
351	NT	NT	NT	NT	NT	NT	NT	NT			

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Without DTT				Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength
112	Negative	Negative	Negative	Negative	1	1	2	1	NT	NT	NT	NT	NT	NT	NT	NT
120	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
128	Negative	Negative	Negative	Negative	1	1	1	1	NT	NT	NT	NT	NT	NT	NT	NT
133	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Positive	Negative	-	-	85%	-
139	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
147	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
154	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
189	Negative	Negative	Negative	Negative	1	1	1	1	NT	NT	NT	NT	NT	NT	NT	NT
193	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
232	Negative	Negative	Positive	Negative	0	0	2	0	NT	NT	NT	NT	NT	NT	NT	NT
238	Negative	Negative	Negative	Negative	1	1	2	1	Negative	Negative	Negative	Negative	1	1	1	1
245	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
262	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Negative	Negative	-	-	-	-
292	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive	-	-	-	4
293	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	-	-	-	-

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B7, B57; Cw6, Cw7; DR7, DR15; DQ6, DQ9

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			29	29	29	29	20	19	19	19	
Positive			0	0	1	1	1	2	14	1	
Negative			29	29	28	28	19	17	5	18	
NT/Equivocal			1	1	1	1	4	5	5	5	
% Positive			0.0%	0.0%	3.4%	3.4%	5.0%	10.5%	73.7%	5.3%	
% Negative			100.0%	100.0%	96.6%	96.6%	95.0%	89.5%	26.3%	94.7%	
Consensus			Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed	Negative	
HLA Antibody Specificity (Defined By CDC)			A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	A1 (DR3)	B5 A3 DR8 DR52	DR7	Cw4 B49 B46 DR1	
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	YES	NO	Negative	Negative	Negative	Negative					
119	YES	NO	Negative	Negative	Negative	Negative					
120	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
133	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
139	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	YES	NO	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low viability of B cells
147	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
157	NO	YES					Negative	Negative	Positive	Negative	
159	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
181	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
189	YES	NO	Negative	Negative	Negative	Negative					
190	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Not tested due to poor viability for B cells
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
195	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cell mortality too high for valid interpretation
197	YES	YES	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
209	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
216	YES	NO	Negative	Negative	Negative	Negative					
229	YES	NO	Negative	Negative	Negative	Negative					
235	YES	NO	Negative	Negative	Negative	Negative					
238	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
245	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
252	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
260	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Results could not be interpreted due to the poor cell viability
262	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
292	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
293	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
294	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Equivocal	Negative	Poor cell viability lead to difficult interpretation on B cells. Routinely another cell sample would be requested
321	YES	YES	Negative	Negative	Negative	Negative	Negative	NT	Positive	NT	B cell serum 2 and 4: a technical problem occurred, the control IgM with DTT was found positive and the reactions are uninterpretable

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	1	1	2	1					70		
119	1	1	1	1					95		
120	1	1	1	1	1	1	6	1	99		
133	0	0	0	0	0	0	0	0		90	60
139	1	1	1	1	NT	NT	NT	NT	80	80	
143	1	1	1	1						90	
147	1	1	1	1	1	4	6	1		100	100
157					1	1	8	1	80	80	50
159	1	1	1	1	1	1	1	1		90	80
169	1	1	1	1	1	1	8	1		99	96
181	1	1	1	1	1	1	4	1		100	100
189	1	1	1	1					88		
190	1%	1%	1%	1%	NT	NT	NT	NT		99	NT
193	1	1	1	1	1	1	4	1	99	99	90
194	-	-	-	-	-	-	8	-	100		
195	1	1	1	1	NT	NT	NT	NT	80		20
197	-	-	weak	weak	-	-	weak	weak	90	85	85
209	1	1	1	1	1	1	6	1	95		
216	1	1	1	1					85		
229	-	-	-	-					90		
235	1	1	2	1					85		
238	1	1	1	1	1	1	8	1	95	90	60
245	1	1	1	1	1	1	8	1	100	100	100
252	1	1	1	1	1	1	1	1	75		55
260	NT	NT	NT	NT	NT	NT	NT	NT		70	30
262	-	-	-	-	-	-	-	-	100	100	100
292	-	-	-	-	6	8	-	-		96	20
293	-	-	-	-	-	-	8	-		80	80
294	0	0	0	0	0	0	8	0		95	95
297	1	1	1	1	1	1	2	1	70	70	70
321	1	1	1	1	1	NT	8	NT		95	98

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2016 OS PC

DISPATCHED ON 26TH JULY 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
112	Negative	Negative	Negative	Negative	1	1	2	1	NT	NT	NT	NT	NT	NT	NT	NT
120	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
128	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
133	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Negative	Negative	-	-	-	-
139	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
147	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	1	1	1	1
154	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
189	Negative	Negative	Negative	Negative	1	1	1	1	NT	NT	NT	NT	NT	NT	NT	NT
193	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
232	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
238	Negative	Negative	Negative	Negative	1	1	2	1	Negative	Negative	Negative	Negative	1	1	1	1
245	Negative	Negative	Negative	Negative	1	1	1	1	Negative	Negative	Negative	Negative	1	1	1	1
262	Negative	Negative	Negative	Negative	-	-	-	-	Negative	Negative	Negative	Negative	-	-	-	-
292	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	-	-	-	-
293	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Negative	-	-	-	-